HomeAbout

TL;DR CNBC


Neuralink competitor Synchron to ramp up brain implant production with equity stake in manufacturer - TL;DR CNBC

Neuralink competitor Synchron to ramp up brain implant production with equity stake in manufacturer

Publishing timestamp: 2024-02-01 07:00:01


Summary

Neurotech startup Synchron is increasing production of its brain-computer interface device in preparation for commercial demand. The company has acquired a minority equity stake in German manufacturer Acquandas, which provides a unique metal layering technology for Synchron's implant. Synchron's BCI allows people with limited physical mobility to operate technology with their mind. The company has implanted patients in the US and Australia and will need to conduct additional trials before gaining regulatory approval. Synchron has caught the attention of investors like Bill Gates and Jeff Bezos, as well as Elon Musk, who owns Neuralink. Synchron's less-invasive approach to implantation makes it more accessible, and the company is planning to launch a patient registry to gauge interest.


Sentiment: POSITIVE

Tickers: AMZNTSLAMSFT

Keywords: enterprisetechnologyjeff bezosinternethealth care industryelon muskbusiness newsbill gatesbreaking news: technologytesla inc

Source: https://www.cnbc.com/2024/02/01/neuralink-competitor-synchron-buys-equity-stake-in-manufacturer.html


Developed by Leo Phan